{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:36:38Z","timestamp":1790746598635,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH NCI P50 CA211015"],"award-info":[{"award-number":["NIH NCI P50 CA211015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH NCI P50 CA211015"],"award-info":[{"award-number":["NIH NCI P50 CA211015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH NCI P50 CA211015"],"award-info":[{"award-number":["NIH NCI P50 CA211015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH NCI P50 CA211015"],"award-info":[{"award-number":["NIH NCI P50 CA211015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH NCI R01CA279984"],"award-info":[{"award-number":["NIH NCI R01CA279984"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DoD CA20029"],"award-info":[{"award-number":["DoD CA20029"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recurrent glioblastomas showing a survival benefit from anti-VEGF agents are known to exhibit a distinct diffusion MRI phenotype. We aim to characterize advanced imaging features of this glioblastoma subset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MRI scans from 87 patients with IDH-wildtype glioblastoma were analyzed. All patients had completed standard chemoradiation and were anti-VEGF-na\u00efve. Contrast-enhancing tumor segmentations were used to extract: the lowest peak of the double gaussian distribution of apparent diffusion coefficient values (ADC\n                      <jats:sub>L<\/jats:sub>\n                      ) calculated from diffusion MRI, relative cerebral blood flow (rCBV) values from perfusion MRI, MTR\n                      <jats:sub>asym<\/jats:sub>\n                      @ 3ppm from pH-weighted amine CEST MRI, quantitative T\n                      <jats:sub>2<\/jats:sub>\n                      and T\n                      <jats:sub>2<\/jats:sub>\n                      * relaxation times (qT\n                      <jats:sub>2<\/jats:sub>\n                      and qT\n                      <jats:sub>2<\/jats:sub>\n                      *), T\n                      <jats:sub>1<\/jats:sub>\n                      w subtraction map values, and contrast-enhancing tumor volume. Lesions were categorized as high- or low-ADC\n                      <jats:sub>L<\/jats:sub>\n                      using a cutoff of 1240 \u00b5m\n                      <jats:sup>2<\/jats:sup>\n                      \/s, according to previous studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High-ADC\n                      <jats:sub>L<\/jats:sub>\n                      lesions showed significantly lower rCBV (1.02 vs. 1.28,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0057), higher MTR\n                      <jats:sub>asym<\/jats:sub>\n                      @ 3ppm (2.36% vs. 2.10%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0043), and higher qT\n                      <jats:sub>2<\/jats:sub>\n                      (114.8 ms vs. 100.9 ms,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0094), compared to low-ADC\n                      <jats:sub>L<\/jats:sub>\n                      lesions. No group differences were seen in contrast-enhancing tumor volume, T\n                      <jats:sub>1<\/jats:sub>\n                      w subtraction map values, and qT\n                      <jats:sub>2<\/jats:sub>\n                      *, nor in clinical variables such as sex category, MGMT status, and EGFR status. Finally, no clear group-specific preferential locations were seen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Post-chemoradiation glioblastomas with a diffusion MRI phenotype that is known to predict a favorable response to anti-VEGF (ADC\n                      <jats:sub>L<\/jats:sub>\n                      \u22651240 \u00b5m\n                      <jats:sup>2<\/jats:sup>\n                      \/s) have distinct biological features, with different perfusion and metabolic characteristics, and T\n                      <jats:sub>2<\/jats:sub>\n                      relaxation times.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-025-05019-8","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:00:10Z","timestamp":1744603210000},"page":"583-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response"],"prefix":"10.1007","volume":"173","author":[{"given":"Francesco","family":"Sanvito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kryukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Teraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phioanh L.","family":"Nghiemphu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Liau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Everson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaine S.C.","family":"Eldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Salamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Ellingson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"5019_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C et al (2023) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neuro Oncol 25:iv1\u2013iv99. https:\/\/doi.org\/10.1093\/neuonc\/noad149","journal-title":"Neuro Oncol"},{"key":"5019_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/359845a0","volume":"359","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845\u2013848. https:\/\/doi.org\/10.1038\/359845a0","journal-title":"Nature"},{"key":"5019_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11060-005-9103-z","volume":"78","author":"RL Jensen","year":"2006","unstructured":"Jensen RL, Ragel BT, Whang K, Gillespie D (2006) Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 78:233\u2013247. https:\/\/doi.org\/10.1007\/s11060-005-9103-z","journal-title":"J Neurooncol"},{"key":"5019_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"5019_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"5019_CR6","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","volume":"31","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Mulholland P, Neyns B et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 31:3212\u20133218. https:\/\/doi.org\/10.1200\/JCO.2012.47.2464","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"5019_CR7","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-16-2844","volume":"23","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Gerstner ER, Smits M et al (2017) Diffusion MRI phenotypes predict overall survival benefit from Anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials. Clin cancer Res Off J Am Assoc Cancer Res 23:5745\u20135756. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2844","journal-title":"Clin cancer Res Off J Am Assoc Cancer Res"},{"key":"5019_CR8","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/neuonc\/noaa120","volume":"22","author":"M Schell","year":"2020","unstructured":"Schell M, Pfl\u00fcger I, Brugnara G et al (2020) Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro Oncol 22:1667\u20131676. https:\/\/doi.org\/10.1093\/neuonc\/noaa120","journal-title":"Neuro Oncol"},{"key":"5019_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3174\/ajnr.A3748","volume":"35","author":"BM Ellingson","year":"2014","unstructured":"Ellingson BM, Sahebjam S, Kim HJ et al (2014) Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol 35:673\u2013679. https:\/\/doi.org\/10.3174\/ajnr.A3748","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR10","doi-asserted-by":"publisher","first-page":"14819","DOI":"10.1038\/s41598-020-71799-w","volume":"10","author":"KS Patel","year":"2020","unstructured":"Patel KS, Yao J, Raymond C et al (2020) Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Sci Rep 10:14819. https:\/\/doi.org\/10.1038\/s41598-020-71799-w","journal-title":"Sci Rep"},{"key":"5019_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1148\/radiol.2521081534","volume":"252","author":"WB Pope","year":"2009","unstructured":"Pope WB, Kim HJ, Huo J et al (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182\u2013189. https:\/\/doi.org\/10.1148\/radiol.2521081534","journal-title":"Radiology"},{"key":"5019_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11060-012-0847-y","volume":"108","author":"WB Pope","year":"2012","unstructured":"Pope WB, Qiao XJ, Kim HJ et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108:491\u2013498. https:\/\/doi.org\/10.1007\/s11060-012-0847-y","journal-title":"J Neurooncol"},{"key":"5019_CR13","doi-asserted-by":"publisher","first-page":"vdab082","DOI":"10.1093\/noajnl\/vdab082","volume":"3","author":"BM Ellingson","year":"2021","unstructured":"Ellingson BM, Patel K, Wang C et al (2021) Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neuro-oncology Adv 3:vdab082. https:\/\/doi.org\/10.1093\/noajnl\/vdab082","journal-title":"Neuro-oncology Adv"},{"key":"5019_CR14","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-23-1235","volume":"29","author":"BM Ellingson","year":"2023","unstructured":"Ellingson BM, Hagiwara A, Morris CJ et al (2023) Depth of radiographic response and time to tumor regrowth predicts overall survival following Anti-VEGF therapy in recurrent glioblastoma. Clin cancer Res Off J Am Assoc Cancer Res 29:4186\u20134195. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1235","journal-title":"Clin cancer Res Off J Am Assoc Cancer Res"},{"key":"5019_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/jmrb.1994.1037","volume":"103","author":"PJ Basser","year":"1994","unstructured":"Basser PJ, Mattiello J, LeBihan D (1994) Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson B 103:247\u2013254","journal-title":"J Magn Reson B"},{"key":"5019_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jmri.22068","volume":"31","author":"BM Ellingson","year":"2010","unstructured":"Ellingson BM, Malkin MG, Rand SD et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538\u2013548. https:\/\/doi.org\/10.1002\/jmri.22068","journal-title":"J Magn Reson Imaging"},{"key":"5019_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13244-019-0724-8","volume":"10","author":"C Durand-Mu\u00f1oz","year":"2019","unstructured":"Durand-Mu\u00f1oz C, Flores-Alvarez E, Moreno-Jimenez S, Roldan-Valadez E (2019) Pre-operative apparent diffusion coefficient values and tumour region volumes as prognostic biomarkers in glioblastoma: correlation and progression-free survival analyses. Insights Imaging 10:36. https:\/\/doi.org\/10.1186\/s13244-019-0724-8","journal-title":"Insights Imaging"},{"key":"5019_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2","volume":"9","author":"T Sugahara","year":"1999","unstructured":"Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53\u201360. https:\/\/doi.org\/10.1002\/(sici)1522-2586(199901)9:1%3C53::aid-jmri7%3E3.0.co;2-2","journal-title":"J Magn Reson Imaging"},{"key":"5019_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11307-014-0807-3","volume":"17","author":"E Karavaeva","year":"2015","unstructured":"Karavaeva E, Harris RJ, Leu K et al (2015) Relationship between [18F]FDOPA PET uptake, apparent diffusion coefficient (ADC), and proliferation rate in recurrent malignant gliomas. Mol Imaging Biol 17:434\u2013442. https:\/\/doi.org\/10.1007\/s11307-014-0807-3","journal-title":"Mol Imaging Biol"},{"key":"5019_CR20","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/jnci\/92.24.2029","volume":"92","author":"TL Chenevert","year":"2000","unstructured":"Chenevert TL, Stegman LD, Taylor JM et al (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029\u20132036. https:\/\/doi.org\/10.1093\/jnci\/92.24.2029","journal-title":"J Natl Cancer Inst"},{"key":"5019_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1023\/a:1006431120031","volume":"50","author":"RK Gupta","year":"2000","unstructured":"Gupta RK, Cloughesy TF, Sinha U et al (2000) Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 50:215\u2013226. https:\/\/doi.org\/10.1023\/a:1006431120031","journal-title":"J Neurooncol"},{"key":"5019_CR22","first-page":"1419","volume":"27","author":"Y Hayashida","year":"2006","unstructured":"Hayashida Y, Hirai T, Morishita S et al (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27:1419\u20131425","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR23","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/1522-2594(200006)43:6<828::aid-mrm8>3.0.co;2-p","volume":"43","author":"H Lyng","year":"2000","unstructured":"Lyng H, Haraldseth O, Rofstad EK (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828\u2013836. https:\/\/doi.org\/10.1002\/1522-2594(200006)43:6%3C828::aid-mrm8%3E3.0.co;2-p","journal-title":"Magn Reson Med"},{"key":"5019_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3174\/ajnr.A3315","volume":"34","author":"S Rose","year":"2013","unstructured":"Rose S, Fay M, Thomas P et al (2013) Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-fluoro-L-dopa PET: what are we really measuring with minimum ADC? AJNR Am J Neuroradiol 34:758\u2013764. https:\/\/doi.org\/10.3174\/ajnr.A3315","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3174\/ajnr.A2917","volume":"33","author":"WB Pope","year":"2012","unstructured":"Pope WB, Mirsadraei L, Lai A et al (2012) Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol 33:1059\u20131064. https:\/\/doi.org\/10.3174\/ajnr.A2917","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3174\/ajnr.A4898","volume":"37","author":"HS Nguyen","year":"2016","unstructured":"Nguyen HS, Milbach N, Hurrell SL et al (2016) Progressing Bevacizumab-Induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in patients with recurrent glioblastoma. AJNR Am J Neuroradiol 37:2201\u20132208. https:\/\/doi.org\/10.3174\/ajnr.A4898","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR27","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3174\/ajnr.A3053","volume":"33","author":"S Mong","year":"2012","unstructured":"Mong S, Ellingson BM, Nghiemphu PL et al (2012) Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 33:1763\u20131770. https:\/\/doi.org\/10.3174\/ajnr.A3053","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR28","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8396","author":"BM Ellingson","year":"2024","unstructured":"Ellingson BM, Sanvito F, Cloughesy TF et al (2024) A neuroradiologist\u2019s guide to operationalizing the response assessment in Neuro-Oncology (RANO) criteria version 2.0 for gliomas in adults. AJNR Am J Neuroradiol. https:\/\/doi.org\/10.3174\/ajnr.A8396","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR29","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/neuonc\/nov095","volume":"17","author":"BM Ellingson","year":"2015","unstructured":"Ellingson BM, Bendszus M, Boxerman J et al (2015) Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol 17:1188\u20131198. https:\/\/doi.org\/10.1093\/neuonc\/nov095","journal-title":"Neuro Oncol"},{"key":"5019_CR30","doi-asserted-by":"publisher","unstructured":"Sanvito F, Kaufmann TJ, Cloughesy TF et al (2023) Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration. Front Radiol 3. https:\/\/doi.org\/10.3389\/fradi.2023.1267615","DOI":"10.3389\/fradi.2023.1267615"},{"key":"5019_CR31","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3174\/ajnr.A4759","volume":"37","author":"K Leu","year":"2016","unstructured":"Leu K, Boxerman JL, Cloughesy TF et al (2016) Improved leakage correction for Single-Echo dynamic susceptibility contrast perfusion MRI estimates of relative cerebral blood volume in High-Grade gliomas by accounting for bidirectional contrast agent exchange. AJNR Am J Neuroradiol 37:1440\u20131446. https:\/\/doi.org\/10.3174\/ajnr.A4759","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10215-z","author":"F Sanvito","year":"2023","unstructured":"Sanvito F, Raymond C, Cho NS et al (2023) Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-023-10215-z","journal-title":"Eur Radiol"},{"key":"5019_CR33","doi-asserted-by":"publisher","first-page":"11922","DOI":"10.1038\/s41598-020-68733-5","volume":"10","author":"J Yao","year":"2020","unstructured":"Yao J, Hagiwara A, Raymond C et al (2020) Human IDH mutant 1p\/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Sci Rep 10:11922. https:\/\/doi.org\/10.1038\/s41598-020-68733-5","journal-title":"Sci Rep"},{"key":"5019_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/neuonc\/noad150","volume":"26","author":"KS Patel","year":"2024","unstructured":"Patel KS, Yao J, Cho NS et al (2024) pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells. Neuro Oncol 26:115\u2013126. https:\/\/doi.org\/10.1093\/neuonc\/noad150","journal-title":"Neuro Oncol"},{"key":"5019_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.18383\/j.tom.2018.00017","volume":"4","author":"J Yao","year":"2018","unstructured":"Yao J, Ruan D, Raymond C et al (2018) Improving B(0) correction for pH-Weighted amine proton chemical exchange saturation transfer (CEST) imaging by use of k-Means clustering and lorentzian Estimation. Tomogr (Ann Arbor Mich) 4:123\u2013137. https:\/\/doi.org\/10.18383\/j.tom.2018.00017","journal-title":"Tomogr (Ann Arbor Mich)"},{"key":"5019_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/radiol.13131305","volume":"271","author":"BM Ellingson","year":"2014","unstructured":"Ellingson BM, Kim HJ, Woodworth DC et al (2014) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted Subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271:200\u2013210. https:\/\/doi.org\/10.1148\/radiol.13131305","journal-title":"Radiology"},{"key":"5019_CR37","doi-asserted-by":"publisher","first-page":"vdac184","DOI":"10.1093\/noajnl\/vdac184","volume":"5","author":"AH Abayazeed","year":"2023","unstructured":"Abayazeed AH, Abbassy A, M\u00fceller M et al (2023) NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics. Neuro-oncology Adv 5:vdac184. https:\/\/doi.org\/10.1093\/noajnl\/vdac184","journal-title":"Neuro-oncology Adv"},{"key":"5019_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3174\/ajnr.A3253","volume":"34","author":"BM Ellingson","year":"2013","unstructured":"Ellingson BM, Lai A, Harris RJ et al (2013) Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 34:533\u2013540. https:\/\/doi.org\/10.3174\/ajnr.A3253","journal-title":"AJNR Am J Neuroradiol"},{"key":"5019_CR39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3171\/2023.5.JNS23285","volume":"140","author":"F Sanvito","year":"2024","unstructured":"Sanvito F, Telesca D, Cho NS et al (2024) Small pretreatment lesion size and high sphericity as favorable prognostic factors after laser interstitial thermal therapy in brain metastases. J Neurosurg 140:338\u2013349. https:\/\/doi.org\/10.3171\/2023.5.JNS23285","journal-title":"J Neurosurg"},{"key":"5019_CR40","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00234-004-1268-1","volume":"46","author":"S Minamikawa","year":"2004","unstructured":"Minamikawa S, Kono K, Nakayama K et al (2004) Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology 46:805\u2013811. https:\/\/doi.org\/10.1007\/s00234-004-1268-1","journal-title":"Neuroradiology"},{"key":"5019_CR41","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/mrm.27204","volume":"80","author":"RJ Harris","year":"2018","unstructured":"Harris RJ, Yao J, Chakhoyan A et al (2018) Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magn Reson Med 80:1962\u20131978. https:\/\/doi.org\/10.1002\/mrm.27204","journal-title":"Magn Reson Med"},{"key":"5019_CR42","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/neuonc\/nov028","volume":"17","author":"P Kickingereder","year":"2015","unstructured":"Kickingereder P, Wiestler B, Burth S et al (2015) Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol 17:1139\u20131147. https:\/\/doi.org\/10.1093\/neuonc\/nov028","journal-title":"Neuro Oncol"},{"key":"5019_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-016-2300-0","volume":"131","author":"IE Bennett","year":"2017","unstructured":"Bennett IE, Field KM, Hovens CM et al (2017) Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. J Neurooncol 131:321\u2013329. https:\/\/doi.org\/10.1007\/s11060-016-2300-0","journal-title":"J Neurooncol"},{"key":"5019_CR44","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/neuonc\/not216","volume":"16","author":"KM Schmainda","year":"2014","unstructured":"Schmainda KM, Prah M, Connelly J et al (2014) Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol 16:880\u2013888. https:\/\/doi.org\/10.1093\/neuonc\/not216","journal-title":"Neuro Oncol"},{"key":"5019_CR45","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1038\/s41598-018-37564-w","volume":"9","author":"A Chakhoyan","year":"2019","unstructured":"Chakhoyan A, Yao J, Leu K et al (2019) Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Sci Rep 9:2846. https:\/\/doi.org\/10.1038\/s41598-018-37564-w","journal-title":"Sci Rep"},{"key":"5019_CR46","doi-asserted-by":"publisher","first-page":"52423","DOI":"10.18632\/oncotarget.9387","volume":"7","author":"R Tamura","year":"2016","unstructured":"Tamura R, Tanaka T, Miyake K et al (2016) Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget 7:52423\u201352435. https:\/\/doi.org\/10.18632\/oncotarget.9387","journal-title":"Oncotarget"},{"key":"5019_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2217\/cns.12.36","volume":"2","author":"KV Lu","year":"2013","unstructured":"Lu KV, Bergers G (2013) Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2:49\u201365. https:\/\/doi.org\/10.2217\/cns.12.36","journal-title":"CNS Oncol"},{"key":"5019_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10014-017-0284-x","volume":"34","author":"R Tamura","year":"2017","unstructured":"Tamura R, Tanaka T, Miyake K et al (2017) Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol 34:62\u201377. https:\/\/doi.org\/10.1007\/s10014-017-0284-x","journal-title":"Brain Tumor Pathol"},{"key":"5019_CR49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/neuonc\/now270","volume":"19","author":"TT Liu","year":"2017","unstructured":"Liu TT, Achrol AS, Mitchell LA et al (2017) Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. Neuro Oncol 19:997\u20131007. https:\/\/doi.org\/10.1093\/neuonc\/now270","journal-title":"Neuro Oncol"},{"key":"5019_CR50","doi-asserted-by":"publisher","first-page":"11223","DOI":"10.1038\/s41598-021-90841-z","volume":"11","author":"M Nakajo","year":"2021","unstructured":"Nakajo M, Bohara M, Kamimura K et al (2021) Correlation between amide proton transfer-related signal intensity and diffusion and perfusion magnetic resonance imaging parameters in high-grade glioma. Sci Rep 11:11223. https:\/\/doi.org\/10.1038\/s41598-021-90841-z","journal-title":"Sci Rep"},{"key":"5019_CR51","doi-asserted-by":"publisher","first-page":"e4785","DOI":"10.1002\/nbm.4785","volume":"36","author":"NS Cho","year":"2023","unstructured":"Cho NS, Hagiwara A, Yao J et al (2023) Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. NMR Biomed 36:e4785. https:\/\/doi.org\/10.1002\/nbm.4785","journal-title":"NMR Biomed"},{"key":"5019_CR52","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11060-019-03132-z","volume":"142","author":"J Yao","year":"2019","unstructured":"Yao J, Tan CHP, Schlossman J et al (2019) pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. J Neurooncol 142:587\u2013595. https:\/\/doi.org\/10.1007\/s11060-019-03132-z","journal-title":"J Neurooncol"},{"key":"5019_CR53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/radiol.2020191376","volume":"295","author":"JE Park","year":"2020","unstructured":"Park JE, Kim HS, Park SY et al (2020) Identification of early response to Anti-Angiogenic therapy in recurrent glioblastoma: amide proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI. Radiology 295:397\u2013406. https:\/\/doi.org\/10.1148\/radiol.2020191376","journal-title":"Radiology"},{"key":"5019_CR54","doi-asserted-by":"publisher","unstructured":"Springer E, Cardoso PL, Strasser B et al (2022) MR Fingerprinting-A radiogenomic marker for diffuse gliomas. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14030723","DOI":"10.3390\/cancers14030723"},{"key":"5019_CR55","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/jmri.20335","volume":"21","author":"J Oh","year":"2005","unstructured":"Oh J, Cha S, Aiken AH et al (2005) Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging 21:701\u2013708. https:\/\/doi.org\/10.1002\/jmri.20335","journal-title":"J Magn Reson Imaging"},{"key":"5019_CR56","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1158\/1078-0432.CCR-14-2862","volume":"21","author":"BM Ellingson","year":"2015","unstructured":"Ellingson BM, Lai A, Nguyen HN et al (2015) Quantification of nonenhancing tumor burden in gliomas using effective T2 maps derived from dual-echo turbo spin-echo MRI. Clin Cancer Res 21:4373\u20134383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2862","journal-title":"Clin Cancer Res"},{"key":"5019_CR57","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/nbm.3611","volume":"29","author":"RJ Harris","year":"2016","unstructured":"Harris RJ, Cloughesy TF, Liau LM et al (2016) Simulation, Phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. NMR Biomed 29:1563\u20131576. https:\/\/doi.org\/10.1002\/nbm.3611","journal-title":"NMR Biomed"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05019-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T06:48:19Z","timestamp":1750056499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05019-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["5019"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05019-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection and analysis of clinical and imaging data for this research was approved by the institutional review board under the identification number IRB#19-002084.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"BME is on the advisory board and is a paid consultant for Medicenna, MedQIA, Servier Pharmaceuticals, Siemens, Janssen Pharmaceuticals, Imaging Endpoints, Kazia, Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Neosoma, Alpheus Medical, Sagimet Biosciences, Sapience Therapeutics, Orbus Therapeutics, and the Global Coalition for Adap- tive Research (GCAR). TFC is cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, holds stock for Erasca, member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research, holds stock in Chimerix and receives milestone payments and possible future royalties, member of the scientific advisory board for Break Through Cancer, member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to Blue Rock, Vida Ventures, Lista Therapeutics, Stemline, Novartis, Roche, Sonalasense, Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Odonate Thera- peutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyo- pharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Novocure, Novogen, Boston Biomedical, Sunovion, Insys, Pfizer, Notable labs, Medqia, Trizel, Medscape and has contracts with UCLA for the Brain Tumor Program with Roche, VBI, Merck, Novartis, BMS, AstraZeneca, Servier. The Regents of the University of California (T.F.C. employer) has licensed intellectual property co-invented by TFC to Katmai Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}